Skip to main content

Allovir Inc

For the period ended Mar 31, 2024. Filed May 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

KLRS$1.87-18.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
(in thousands, except share amounts)SharesAmountCapitalLossDeficitEquity
Balance at December 31, 202293,093,243$9$690,753$(468)$(465,775)$224,519
Stock-based compensation——10,029——10,029
Issuance of common stock, upon vesting of restricted stock334,747—————
Unrealized gain on available-for-sale securities———167—167
Net loss————(41,183)(41,183)
Balance at March 31, 202393,427,990$9$700,782$(301)$(506,958)$193,532

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
(in thousands, except share amounts)SharesAmountCapitalLossDeficitEquity
Balance at December 31, 2023114,148,991$11$802,025$(62)$(656,193)145,781
Stock-based compensation——5,034——5,034
Issuance of common stock, upon vesting of restricted stock732,774—————
Unrealized loss on available-for-sale securities———(76)—(76)
Net loss————(30,299)(30,299)
Balance at March 31, 2024114,881,765$11$807,059$(138)$(686,492)$120,440
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.